MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

By T. Powles, J. Eder, G. Fine, F. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H. Burris, D. Petrylak, S. Teng and 5 more. Nature, 2014

2,264 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/26c930017c6d5c3a72cf377e304e00f7a03c42d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

In Surgery

J. Engelman

Citations in the corpus

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. (2016, background): “ronment may also express PD-L1 and similarly inhibit T-cell responses at the tumor site.(13) To date, PD-1 monoclonal antibodies nivolumab and pembrolizumab have been approved for the treatment of advanced melanoma, non–small-cell lung cancer, and renal cell carcinoma (nivolumab only).”
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review (2017, neutral): “agent [9, 11–35], 35% an anti-PD-1 agent [3, 4, 6–8, 36–47] and 4% an anti-PD-L1 ICI [48, 49].”
Classifying cancers based on T cell infiltration and PD-L1 (2015, positive): “Anti–PD-1 may also be either substituted or combined with various anti–PD-L1 mAbs (MPDL3280A, BMS 936559, MSB0010718C), which are currently being evaluated in clinical trials (11, 12, 45).”
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features (2017, neutral): “5 g/L 26 (12) 13 (11) 42 (31) Platelet count, 41 (18) 17 (13) N/A AFP, >100 mg/dL (%) 51 (23) 38 (31) 43 (33) Events (%) Recurrence 150 (67) 78 (60) 88 (59) Death 133 (59) 46 (35) 84 (44) Median follow-up, months 49 51 N/A”
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, background): “Fatigue (2%, n = 5) Low appetite (0%, n = 0) Rash (0%, n = 0) Influenza-like illness (<1%, n = 1) AST/ALT elevation (2%, n = 6) Tumor lysis syndrome (<1%, n = 2) Powles (2014) [6] I Urothelial carcinoma 68 15 mg/kg every 3 weeks × 1 year Total = 57% (n = 39) Low appetite (12%, n = 8) Fatigue (12%, n”
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. (2015, positive): “While IFN-γ can promote TIL effector functions by increasing TIL differentiation and stimulating antigen processing and presentation (20, 21), cell surface PD-L1 binds its receptors on Teffs, including PD-1 and B7-1, thereby paralyzing T cells.”